- Molecular NameTestolactone
- SynonymTestolactona [INN-Spanish]; Testolactonum [INN-Latin]; Testolattone [Dcit]
- Weight300.398
- Drugbank_IDDB00894
- ACS_NO968-93-4
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.67
- pkaN/A
- LogD (pH=7, predicted)3.67
- Solubility (experiment)0.0274 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-4.28
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds0
- TPSA43.37
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antineoplastic agent that is a derivative of progesterone and is used to treat advanced stage breast cancer.
- Absorption_valueN/A
- Absorption (description)Testolactone is well absorbed from the gastrointestinal tract.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding85.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Metabolized to several derivatives in the liver, all of which preserve the lactone D-ring.
- Half lifeN/A
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)LD50=1630 mg/kg